Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2004

View Archived Issues

Phase I studies evaluate the effects of SPD-754 on the metabolism of other anti-HIV drugs

Novel class of HIV-1 entry inhibitors targets gp120-binding domain of CD4

A recombinant vaccine shows promise in the prevention of SARS

Signet outlines plans for efforts in sepsis and acute renal failure

Celera Genomics and Seattle Genetics to develop antibody therapies for cancer

Several drugs show efficacy in the treatment of HIV-associated lipodystrophy

Hypocholesterolemic compound reduces Abeta levels in vivo

PBI-1393 activates CTLs and induces IL-2 and IFN-gamma synthesis

Flurbiprofen analogues reduce beta-amyloid release without affecting COX-1 activity

FDA to grant additional six months pediatric exclusivity to clofarabine

AzaSite enters two phase III studies for acute bacterial conjunctivitis

ViroPharma to advance maribavir into phase II

Atrix licenses BEMA technology to Arius

Pfizer to discontinue development of sumanirole

Access updates progress of AP-5346

DMAG enters phase I

Evotec to support Morphochem's development of Oxaquin

NEC discovers new peptide-vaccine candidates for hepatitis C

LY-450139 reported to reduce the levels of amyloid beta in plasma and CSF

Farnesoid X receptor agonists

New JNK3 inhibitors with potential utility in cerebral ischemia

Selective 5-HT6 antagonists claimed by Roche

Prodrugs of MPV-2426 described by Orion

Boehringer Ingelheim discloses anti-HIV agents

Glucokinase activators described by Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...